Technical Analysis for OMER - Omeros Corporation

Grade Last Price % Change Price Change
D 17.42 2.89% 0.49
OMER closed down 7.13 percent on Monday, April 12, 2021, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Down
Historical OMER trend table...

Date Alert Name Type % Chg
180 Bearish Setup Bearish Swing Setup 2.89%
Lower Bollinger Band Touch Weakness 2.89%
Oversold Stochastic Weakness 2.89%
Outside Day Range Expansion -4.44%
Oversold Stochastic Weakness -4.44%
Narrow Range Bar Range Contraction -1.64%
NR7 Range Contraction -1.64%
Inside Day Range Contraction -1.64%
Oversold Stochastic Weakness -1.64%
Lower Bollinger Band Touch Weakness -2.79%
Older End-of-Day Signals for OMER ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 2% about 1 hour ago
60 Minute Opening Range Breakout about 5 hours ago
Down 1% about 6 hours ago
Up 1% about 6 hours ago
Bearish 180 Entry about 6 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Omeros Corporation Description

Omeros Corporation, a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing products targeting inflammation, coagulopathies, and disorders of the central nervous system. The company derives product candidates from its proprietary PharmacoSurgery platform that is designed to enhance clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological, and other surgical and medical procedures. The company's product candidates include OMS302, which has completed two Phase III clinical trials for use during intraocular lens replacement surgery, including cataract and other lens replacement surgery; OMS103HP that is in Phase III program for use during arthroscopic procedures comprising partial meniscectomy surgery; and OMS201, which has completed Phase I/Phase II studies for use during urological procedures, including ureterscopy for removal of ureteral or renal stones. Its clinical programs also consist of OMS824, which is in Phase I clinical trial for the treatment of cognitive disorders, including schizophrenia; and OMS405 that is in Phase II clinical trial for the treatment and prevention of addiction to substances of abuse. The company's preclinical product development programs comprise OMS721 for hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria, wet age-related macular degeneration, ischemia-reperfusion injury, and transplant-related complications; OMS527 for addictions and compulsive disorders, and movement disorders; and OMS616 for surgical and traumatic bleeding. In addition, it is developing G protein-coupled receptors (GPCR) programs for multiple disorders. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Surgery Inflammation Injury Clinical Research Clinical Trial Disorders Urology Macular Degeneration Ophthalmology Schizophrenia Related Macular Degeneration Hemoglobin Wet Age Related Macular Degeneration Perfusion Movement Disorders Cataract Cognitive Disorders Ischemia Surgical Specialties Hemoglobinuria Paroxysmal Nocturnal Hemoglobinuria Addiction Intraocular Lens Arthroscopy Hemolytic Uremic Syndrome

Is OMER a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 25.46
52 Week Low 9.25
Average Volume 657,135
200-Day Moving Average 14.88
50-Day Moving Average 19.92
20-Day Moving Average 18.73
10-Day Moving Average 17.89
Average True Range 0.97
ADX 28.8
+DI 10.80
-DI 24.36
Chandelier Exit (Long, 3 ATRs ) 17.56
Chandelier Exit (Short, 3 ATRs ) 19.69
Upper Bollinger Band 20.55
Lower Bollinger Band 16.91
Percent B (%b) 0.01
BandWidth 19.41
MACD Line -0.57
MACD Signal Line -0.45
MACD Histogram -0.1176
Fundamentals Value
Market Cap 1.04 Billion
Num Shares 61.7 Million
EPS -2.08
Price-to-Earnings (P/E) Ratio -8.14
Price-to-Sales 7.09
Price-to-Book 0.00
PEG Ratio -0.17
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.12
Resistance 3 (R3) 19.31 18.77 18.76
Resistance 2 (R2) 18.77 18.21 18.68 18.63
Resistance 1 (R1) 17.85 17.87 17.58 17.66 18.51
Pivot Point 17.31 17.31 17.18 17.22 17.31
Support 1 (S1) 16.39 16.75 16.12 16.20 15.35
Support 2 (S2) 15.85 16.41 15.76 15.23
Support 3 (S3) 14.93 15.85 15.11
Support 4 (S4) 14.74